A decade ago, the emergence of new immunotherapies in the cell and gene therapy (CGT) space opened up new avenues to treat disease, sparking excitement across the industry. However, the path to commercialization has been a steep learning curve for both companies and regulatory agencies given the uncharted waters of these new modalities. Now that […]